To test this hypothesis, we applied each of the CDKi in combination with daunorubicin to ABCB1-expressing cells, both genetically modified and cancer-derived, to evaluate whether CDKi can synergistically potentiate daunorubicin’s cytotoxic effects. Here, ABCB1 is linked to cancer.